📊 EBS Key Takeaways
Is Emergent BioSolutions Inc. (EBS) a Good Investment?
Emergent BioSolutions exhibits severe financial distress with an interest coverage ratio of 0.4x, indicating the company cannot service its $589.7M debt from operating income. Compounding this crisis, the company generated negative operating cash flow of -$33.8M and free cash flow of -$36.2M, demonstrating unsustainable cash burn. Combined with zero revenue growth and extremely poor returns (ROE 1.3%, ROA 0.5%), the company faces imminent refinancing or restructuring risks.
Emergent BioSolutions shows a meaningful improvement in earnings and cash generation, with net income more than doubling year over year and free cash flow reaching a strong 21.1% margin. However, revenue was flat, leverage remains elevated, and interest coverage is only moderate, which limits the strength of the improvement and suggests the turnaround still needs to prove durability.
Why Buy Emergent BioSolutions Inc. Stock? EBS Key Strengths
- Strong liquidity position with current ratio of 4.29x and $160.3M cash reserves providing short-term operational runway
- Net income improved 127.6% year-over-year, showing recent operational progress from depressed base
- Gross profit of $261M exceeds revenue, suggesting potential for margin recovery if operational efficiency improves
- Strong free cash flow generation with $156.8M of free cash flow and a 21.1% FCF margin
- Excellent near-term liquidity, supported by a 5.01x current ratio and $205.4M in cash
- Profitability improved materially year over year, with net income and diluted EPS both up more than 125%
EBS Stock Risks: Emergent BioSolutions Inc. Investment Risks
- Critical: Interest coverage ratio of 0.4x means operating income cannot cover debt service obligations—indicates high default risk
- Persistent negative operating cash flow (-$33.8M) and negative free cash flow (-$36.2M) are unsustainable; company is burning cash despite positive net income
- Complete revenue stagnation (0% YoY growth) with microscopic margins (4.4% net) leaves no buffer for debt obligations or adverse events
- Debt-to-equity ratio of 1.13x combined with operational losses suggests potential covenant violations or forced restructuring
- Abnormally elevated gross margin (167.2%) raises data quality concerns and masks true operational performance
- Revenue stagnation at $742.9M raises concern about how sustainable earnings growth will be without top-line expansion
- Leverage is still meaningful, with $589.7M of long-term debt and a 1.13x debt-to-equity ratio
- Interest coverage of 4.1x leaves less room for operational setbacks or margin compression
Key Metrics to Watch
- Interest coverage ratio—must exceed 1.5x to reduce default risk
- Operating cash flow—must turn positive to validate business sustainability
- Revenue growth trajectory—stagnation at 0% YoY is unacceptable for debt service
- Debt refinancing activity and covenant compliance
- Cash burn rate and runway remaining before liquidity crisis
- Revenue growth and segment mix improvement
- Debt reduction and interest coverage trend
Emergent BioSolutions Inc. (EBS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.29x current ratio provides a solid financial cushion.
EBS Profit Margin, ROE & Profitability Analysis
EBS vs Healthcare Sector: How Emergent BioSolutions Inc. Compares
How Emergent BioSolutions Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Emergent BioSolutions Inc. Stock Overvalued? EBS Valuation Analysis 2026
Based on fundamental analysis, Emergent BioSolutions Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Emergent BioSolutions Inc. Balance Sheet: EBS Debt, Cash & Liquidity
EBS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Emergent BioSolutions Inc.'s revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $-14.85 indicates the company is currently unprofitable.
EBS Revenue Growth, EPS Growth & YoY Performance
EBS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $156.1M | $6.8M | $0.07 |
| Q3 2025 | $231.1M | $9.0M | $0.91 |
| Q2 2025 | $140.9M | $9.0M | $-0.22 |
| Q1 2025 | $222.2M | $9.0M | $0.17 |
| Q2 2021 | $394.7M | $4.6M | $0.09 |
| Q1 2021 | $192.5M | -$12.5M | $-0.24 |
| Q3 2020 | $311.8M | $7.6M | $0.15 |
| Q2 2020 | $243.2M | -$9.5M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Emergent BioSolutions Inc. Dividends, Buybacks & Capital Allocation
EBS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Emergent BioSolutions Inc. (CIK: 0001367644)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 4, 2026 | 4 | xslF345X06/wk-form4_1777930251.xml | View → |
| May 4, 2026 | 4 | xslF345X06/wk-form4_1777930221.xml | View → |
| May 4, 2026 | 4 | xslF345X06/wk-form4_1777930168.xml | View → |
| May 4, 2026 | 4 | xslF345X06/wk-form4_1777930151.xml | View → |
| May 4, 2026 | 4 | xslF345X06/wk-form4_1777930137.xml | View → |
❓ Frequently Asked Questions about EBS
What is the AI rating for EBS?
Emergent BioSolutions Inc. (EBS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EBS's key strengths?
Claude: Strong liquidity position with current ratio of 4.29x and $160.3M cash reserves providing short-term operational runway. Net income improved 127.6% year-over-year, showing recent operational progress from depressed base. ChatGPT: Strong free cash flow generation with $156.8M of free cash flow and a 21.1% FCF margin. Excellent near-term liquidity, supported by a 5.01x current ratio and $205.4M in cash.
What are the risks of investing in EBS?
Claude: Critical: Interest coverage ratio of 0.4x means operating income cannot cover debt service obligations—indicates high default risk. Persistent negative operating cash flow (-$33.8M) and negative free cash flow (-$36.2M) are unsustainable; company is burning cash despite positive net income. ChatGPT: Revenue stagnation at $742.9M raises concern about how sustainable earnings growth will be without top-line expansion. Leverage is still meaningful, with $589.7M of long-term debt and a 1.13x debt-to-equity ratio.
What is EBS's revenue and growth?
Emergent BioSolutions Inc. reported revenue of $156.1M.
Does EBS pay dividends?
Emergent BioSolutions Inc. does not currently pay dividends.
Where can I find EBS SEC filings?
Official SEC filings for Emergent BioSolutions Inc. (CIK: 0001367644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EBS's EPS?
Emergent BioSolutions Inc. has a diluted EPS of $0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EBS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Emergent BioSolutions Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EBS stock overvalued or undervalued?
Valuation metrics for EBS: ROE of 1.3% (sector avg: 15%), net margin of 4.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EBS stock in 2026?
Our dual AI analysis gives Emergent BioSolutions Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EBS's free cash flow?
Emergent BioSolutions Inc.'s operating cash flow is $-33.8M, with capital expenditures of $2.4M. FCF margin is -23.2%.
How does EBS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.4% (avg: 12%), ROE 1.3% (avg: 15%), current ratio 4.29 (avg: 2).